Objectives. SLE is an autoimmune disease with increased cardiovascular morbidity and platelet activation. In the general population, increased platelet size predicts platelet reactivity and cardiovascular disease. The aim of this study was to investigate whether platelet size related to platelet activation and cardiovascular disease in SLE.
Introduction
SLE is an autoimmune rheumatic disease characterized by systemic inflammation and involvement of multiple organ systems including skin, joints and kidneys [1] . SLE patients have increased cardiovascular morbidity and mortality, which is only partly explained by traditional cardiovascular risk factors [25] . Recently the role of IFN-a and platelet activation has been implicated in cardiovascular disease in SLE by ourselves and others [610] .
The underlying mechanism(s) causing increased platelet activation in SLE is not known, although aCL and other aPLs have been shown to induce platelet activation [6, 11] and to participate in the development of cardiovascular disease, venous thrombosis and miscarriage related to APS [12] .
Platelets are key regulators of haemostasis and contribute to scar healing and thrombus formation. During the last decades, platelets have been recognized as part of the innate immune system. Platelets express several immunomodulatory molecules and are able to contribute to inflammation, vascular permeability and perhaps also to chronic inflammatory diseases [13] . Upon platelet activation, platelets have three main mechanisms of promoting inflammation and thrombosis: cell surface receptors increasing the adhesive properties of the platelet, release of soluble factors that promote inflammation and thrombus formation and budding of microparticles (MPs) that are able to transfer regulatory miRNA [14] . One of the most prominent platelet cell surface molecules is P-selectin, stored in alpha granules, allowing adherence to leucocytes, including monocytes, plasmacytoid dendritic cells and neutrophils. Binding of platelets to those immune cells will promote tissue factor expression, type I IFN production and release of neutrophil extracellular traps, respectively [1518] . Platelets also release several soluble factors, including the dense granule molecule serotonin, a process recently shown by us to be impaired in lupus [19] . Serotonin is scavenged from the gastrointestinal tract, where it is generated by enterochromaffin cells, and released upon platelet activation to support activation of myeloid cells and endothelium, as well as increase vascular permeability locally [13] . Finally, during either cell death or activation [20] , platelets may generate MPs, particles commonly increased in cardiovascular disease, exposing activating surfaces supporting thrombin generation [21, 22] . However, in the general population, not only are small platelet fragments (e.g. MPs) associated with cardiovascular disease, but also large platelets have been suggested to predict cardiovascular disease and platelet reactivity [2325] . The current literature on platelet size in SLE is scarce and contradictory. In some studies the mean platelet volume (MPV) is increased [26, 27] and related to disease activity [26] , whereas in other studies MPV is inversely associated with disease activity and decreased as compared with healthy controls [2830] . However, the possible association of platelet size to platelet activation and cardiovascular disease has not been investigated in SLE patients.
The aim of the current investigation was to determine whether SLE patients had abnormal platelet size as compared with healthy controls and disease controls and whether platelet size was related to disease activity, markers of platelet activation and cardiovascular disease. In brief, we found that SLE patients had decreased platelet size related to ongoing platelet activation, in particular MP formation and the release of serotonin from dense granules. Finally, in contrast with observations in the general population, no associations were found between platelet size and cardiovascular disease or venous thrombosis. Instead, in SLE patients, decreased platelet size was associated with APS, even after adjusting for cardiovascular risk factors.
Methods

Patients
Patients with SLE (n = 148), RA (n = 20) and SSc (n = 20) were recruited to participate in studies related to cardiovascular disease at the Department of Rheumatology, Skå ne University Hospital, Lund, Sweden. Patients with RA were mainly women [15/20 ( (3/20) and ASA (9/ 20) . Healthy volunteers (n = 79) were age and sex matched to the SLE patients. Inclusion criteria included no prior cardiovascular event or venous thrombosis, no autoimmune disease, no known current infection, as well as a lack of immunosuppressive treatment, ASA or clopidogrel. An overview of the clinical characteristics for the SLE patients is presented in Table 1 .
Disease activity was assessed using SLEDAI-2K [31] . All but two individuals fulfilled at least four ACR 1982 criteria for SLE [32] . Those two patients fulfilled three ACR criteria, had a clinical SLE diagnosis with at least two organ manifestations characteristic of SLE, autoimmune phenomena and no other diagnosis that could better explain the symptoms. Previous episodes of myocardial infarction, cerebrovascular incidents (CVIs), deep venous thrombosis or pulmonary embolisms were defined by the SLICC/ACR Damage Index (DI) [33] irrespective of the time point of SLE diagnosis. APS was defined according to the 2006 classification criteria [12] . Among the 148 SLE patients, 23 (16%) had APS, 10 (7%) had myocardial infarction, 15 (10%) had CVI and 24 (16%) had prior venous thrombosis. Of the 23 SLE patients with secondary APS, 6 (26%) had repeated miscarriage, 13 (56%) had venous thrombosis, 10 (43%) had CVI, 9 (39%) were positive for lupus anticoagulant, 8 (35%) were positive for antib2GP1 and 19 (83%) were positive for aCL. The study was approved by the Lund University local ethics board (LU06014520) and informed consent was obtained from all participants according to the Declaration of Helsinki.
The following treatments were used in the SLE cohort at the time of blood sampling: corticosteroids (n = 98), HCQ (n = 105), AZA (n = 32), MMF (n = 20), MTX (n = 13), IVIG (n = 2), NSAIDs (n = 12), ASA (n = 44) and warfarin (n = 23) and selective serotonin re-uptake inhibitors (SSRIs) or other serotonin transporter antagonists (n = 21). None of the treatments used, except for SSRI [19] , affected any of the measured platelet activation markers statistically significantly. Traditional cardiovascular risk factors including age, gender, smoking, hypertension (systolic blood pressure 5140 mmHg at the time of blood sampling or hypertensive treatment due to high blood pressure) and LDL levels were assessed at the clinic visit.
Measurement of platelet MPs
Flow cytometry was performed directly on EDTA plasma [34] . MPs were labelled with anti-CD61-APC or the relevant control antibody. To reduce background noise, all buffers were filtered through 0.1 mm pore size filters (MiniSart HF, Sartorius Stedim Biotech, Aubagne, France). Labelling was carried out by adding 5 ml heparin-sodium salt 10% w/v (194 USP/mg dry basis; Sigma-Aldrich) to 5 ml plasma followed by the addition of 5 ml anti-CD61-APC (IgG1k, 0.065 mg/ml, clone C7280; Dako, Glostrup, Denmark) or the control antibodies (IgG1k-APC, clone DAK-GO1; Dako). The suspension was diluted to 955 ml in low PBS with citrate (154 mM NaCl, 1.4 mM phosphate, 10.5 mM trisodium citrate, pH 7.4). The samples were analysed using a FACSCalibur flow cytometer (BD, Franklin Lakes, NJ, USA) controlled by CellQuest software version 5.1.1 in the 'high' flow rate mode. Flow rate was measured before each experiment. Both forward scatter (FSC), side scatter (SSC) and FL-4 fluorescence (anti-CD61) were recorded with logarithmic gain. Acquisition time was 60 s. MP gating was accomplished using 1 mm beads (Flow Cytometry Size Calibration Kit, Molecular Probes, Eugene, OR, USA) for setting upper limits in both FSC and SSC signals, and a lower limit was placed to exclude buffer noise as previously described [35] . Data analysis was performed using FlowJo software version 7.6.1 (TreeStar, Ashland, OR, USA). Plasma concentrations (MPs/ml) were calculated on the basis of MP count per unit time, flow rate of the flow cytometer and net dilution during sample preparation.
Platelet activation markers
Blood was collected in sodium citrate tubes (BD Biosciences, San Diego, CA, USA) and used within 15 min. To investigate platelet activation, we interrogated three distinct processes, that is, adhesion to immune cells, release of soluble markers (serotonin) and generation of MPs. Serotonin was measured in plasma using a commercially available ELISA kit according to the manufacturer's instructions (LDN, Nordhorn, Germany). Intracellular platelet serotonin levels were only analysed in some patients, as described previously [19] . For all serotonin analyses, patients using SSRI were excluded due to depletion of peripheral serotonin after such treatment [19] . Plateletlymphocyte complexes were measured by flow cytometry as described previously [9] . Platelet size was determined by the median FSC of isolated platelets as measured by flow cytometry (BD Accuri C6, BD). As a cut-off for low platelet size, the 25th percentile of the healthy volunteers was used. Also, MPV, platelet large cell ratio and platelet distribution width were measured in whole blood using an automatic cell counter (Sysmex, Kobe, Japan).
In vitro platelet activation assay
Platelet activation was performed as described previously [6, 11] . Briefly, platelet-rich plasma was incubated with low concentration adenosine diphosphate (ADP; 0.2 mM; Chrono-log, Havertown, PA, USA), human aCL (20 mg/ml; Antibodies-online.com, Atlanta, GA, USA), human IgG (20 mg/ml; Immuno AG, Vienna, Austria) or combinations for 30 min. Platelet size was determined by flow cytometry as median FSC and platelet activation analysed by P-selectin expression (BD Biosciences Pharmingen).
Statistics
MannWhitney U test and paired t test were used for comparison between patient groups and in vitro experiments, respectively. Spearman's correlation analysis was used for correlations. Logistic regression analysis, adjusted for age, sex and cardiovascular risk factors when applicable, was applied to determine the association between low platelet size and clinical manifestations. GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA) was used for the figures and SPSS Statistics 20 (IBM, Armonk, NY, USA) was used for the statistical calculations. P-values <0.05 were considered statistically significant. Values given as a percentage unless otherwise indicated.
Results
SLE patients have decreased platelet size
As demonstrated by flow cytometry (Fig. 1A) , SLE patients (n = 148) had significantly reduced platelet size as compared with healthy controls (n = 79, P = 0.003; Fig. 1B) . Also, patients with RA and systemic sclerosis had decreased platelet size, although it did not reach statistical significance (P = 0.10 and P = 0.26, respectively; Fig. 1B ). To verify that the decrease in platelet size was not dependent on the platelet isolation procedure prior to flow cytometry analysis, platelet size was also determined in whole blood using an automatic cell counter. A strong correlation between the two methods of measuring platelet size was found in SLE patients (P < 0.0001, r = 0.79; Fig. 1C ). The same was also seen in healthy volunteers (P < 0.0001, r = 0.80), patients with RA (P < 0.0001, r = 0.86) and patients with SSc (P < 0.0001, r = 0.91). To further characterize the platelet morphology we investigated two additional measures of platelets as assessed by the automatic cell counter. Neither the platelet large cell ratio (P = 0.19), measuring the frequency of unusually large platelets or platelet distribution width (P = 0.08), illustrating the heterogeneity of the platelet population, were statistically significantly different between healthy controls and SLE, even if a trend towards smaller and more uniform platelets were seen in SLE patients also using those measures. Thus SLE patients had a decreased platelet size as determined by flow cytometry and this was not dependent on the isolation procedure, that is, platelet isolation by centrifugation (flow cytometry) or whole blood (cell counter).
Platelet size is associated with platelet activation To investigate the relationship between platelet size and platelet activation we interrogated three distinct platelet processes, that is, platelet up-regulation of P-selection and binding to immune cells through the P-selectin glycoprotein ligand-1, platelet degranulation and release of serotonin, as well as generation of platelet-derived MPs. Platelet size was inversely correlated with the amount of platelet-derived MPs (PMPs; P < 0.0001, r = À0.46; Fig. 2A ). Further, patients with small platelets had increased levels of PMPs in the circulation (P < 0.0001; Fig. 2C ), supporting the hypothesis of platelet size being related to platelet activation and degranulation in SLE patients. Finally, platelet serotonin levels correlated with platelet size (P = 0.0007, r = 0.57; Fig. 2D ) and were markedly decreased in small platelets (P = 0.006; Fig. 2E ), in conjunction with increased levels of serotonin in the circulation (P = 0.04; Fig. 2F ). In all, those data suggest that in SLE, small platelets are related to ongoing platelet degranulation, in particular of dense granules and generation of PMPs.
ACL may participate in decreasing platelet size in SLE patients
Even though platelet activation is most likely the consequence of several processes, aCL, commonly found in SLE patients, has been shown by us and others to contribute to platelet activation in some patients [6, 11] . In keeping with a role of aCL in platelet activation, we found that patients with a history of aCL had decreased platelet size as compared with patients without aCL (P = 0.02; Fig. 3A) . Also, patients without aCL had decreased platelet size as compared with healthy controls (P = 0.04), suggesting that other mechanisms likely participate to decrease platelet size in SLE. However, SLE patients with aCL had a markedly decreased platelet size as compared with healthy controls (P = 0.0002; Fig. 3A) . Further, using a logistic regression model, an increase in the platelet size by 1 S.D. was associated with a reduced frequency of aCL [odds ratio (OR) 0.61 (95% CI 0.410.92), P = 0.02; Table 2 ]. To investigate the potential role of aCL in reducing platelet size in vitro, platelets were incubated with a low, suboptimal concentration of ADP, a platelet activating molecule, in the presence of either control human IgG or aCL. Consistent with prior work, the addition of aCL, but not control human IgG at similar levels, amplified ADP-induced platelet activation (P = 0.01; Fig. 3B ). Importantly, aCL, but not human IgG, decreased platelet size, both with and without prior platelet activation (P = 0.01 and P = 0.0007, respectively; Fig. 3C ). Importantly, this was selective for aCL and not seen for ADP activation, suggesting that classical platelet activation is not sufficient to reduce platelet size. Thus aCL is associated with decreased platelet size both in vivo and in vitro in a subset of patients. Further studies are needed to determine the underlying mechanism(s) through which aCL mediates the decrease in platelet size.
Small platelets are associated with APS
After demonstrating that SLE patients had decreased platelet size, we next asked if this had any clinical
FIG. 2 Platelet size is related to platelet degranulation and microparticle formation
Platelet size in SLE patients was related to (A and B) number per millilitre of platelet-derived microparticles (PMPs), (C) fraction of plateletlymphocyte complexes, (D and E) platelet 5-HT levels (n = 31) and (F) plasma 5-HT levels. The cut-off for small and normal platelet size was set by the 25th percentile of the healthy controls.
implications. It had previously been shown that low platelet size is related to increased disease activity in SLE [2830] . However, in our study with 148 SLE patients, we did not find any association between platelet size and overall disease activity as determined by the SLEDAI (P = 0.61, r = 0.04) or any specific disease manifestations, either clinical or serological. In the general population, increased platelet size was related to cardiovascular disease [2325] . However, the potential relation between platelet size and cardiovascular disease in SLE patients had not been investigated. In contrast to the general population, we did not find any associations between platelet size and cardiovascular disease or venous thrombosis in SLE patients (Table 2 ). However, low platelet size was associated with APS [OR 3.58 (95% CI 1.319.82), P = 0.01] when adjusted for traditional cardiovascular risk factors (Table 2) . Finally, using a logistic regression model, an increase in platelet size by 1 S.D. was associated with a reduced prevalence of APS [OR 0.52 (95% CI 0.310.90), P = 0.02; Table 2 ]. Thus, in contrast to previous findings on increased platelet size in cardiovascular disease in the general population [2325], we found that patients with secondary APS had markedly decreased platelet size.
Discussion
SLE is an autoimmune disease with increased cardiovascular morbidity and mortality only partly explained by traditional cardiovascular risk factors [25] . During the last decade, we and others have demonstrated that platelet activation may participate in SLE pathogenesis, including development of cardiovascular disease [611, 19] . In the general population both small PMPs as well as large platelets have been shown to predict cardiovascular disease [2125] . While amounts of PMPs have been shown to be increased in SLE and related to a pro-coagulant state in some but not all studies [3537] , the potential implications of abnormal platelet size in cardiovascular disease in SLE has not been carefully addressed. Using a cohort of non-selected SLE patients we found that, independent of disease activity, SLE patients had decreased platelet size as compared with healthy individuals. Interestingly, patients with other chronic rheumatic diseases (RA and SSc) also had decreased platelet size, although not reaching statistical significance, possibly due to sample size. Even though the current literature is inconsistent, recent work suggests that decreased platelet size   FIG. 3 ACL may reduce platelet size (A) SLE patients were grouped based on their history of aCL (n = 42 aCL + and n = 106 aCL À ) and platelet size (FSC) compared. (B and C) Platelets were incubated with human IgG, aCL antibodies and/or ADP and (B) platelet P-selectin and (C) platelet size analysed by flow cytometry. The results are mean + S.E.M. of n = 5 (B) and n = 7 (C) independent experiments with *P < 0.05, **P < 0.01 and ***P < 0.001. Low platelet size was determined by the 25th percentile of the healthy controls. is seen in several chronic or acute inflammatory conditions, including RA, and may be reversed upon treatment with anti-inflammatory drugs, including anti-TNF-a therapy [38, 39] . Previous work in SLE has suggested that decreased platelet size is most prominent in patients with active disease, including arthritis [28, 29] . However, in our SLE cohort we did not find any association with disease activity or specific clinical manifestations, including nephritis and arthritis, at the time point of blood sampling. However, of note, most of our patients had mild disease at the time of blood draw, with <30% of the included patients having a SLEDAI score of four or more. In contrast to results from the general population [2325], we did not find any association of platelet size with cardiovascular disease or venous thrombosis. However, we made the novel discovery that platelet size is inversely associated with secondary APS, which had not been investigated in previous studies. Of note, venous thrombosis in SLE is not always related to APS, but other mechanisms may also exist. Thus our results suggest that aCL (and APS), but not venous thrombosis as such, may relate to a decreased platelet size in SLE. Interestingly, we observed a trend towards large platelets being associated with the development of myocardial infarction (Table 2 ). Myocardial infarction due to atherosclerosis is not part of APS, and it is thus possible that, similar to the general population, large platelets are associated with the development of certain cardiovascular events in SLE patients. Further studies including more patients are necessary to explore this hypothesis.
The contrasting results, with large platelets being related to cardiovascular disease in the general population and small platelets being related to APS in SLE patients, may suggest different underlying mechanisms affecting platelet size in the general population as compared with autoimmune chronic inflammatory conditions. In the general population it is thought that large platelets, formed due to bone marrow abnormalities, have increased reactivity and may release increased amounts of pro-coagulant molecules locally upon activation, thus promoting thrombus formation [4042] . In SLE, however, platelet size is inversely related to distinct markers of platelet activation, including PMPs and serotonin, well known to contribute to cardiovascular disease [22, 43] . Of note, our study was cross-sectional and we thus only know that decreased platelet size is related to existing APS. It is possible that in SLE, large platelets predict upcoming cardiovascular disease, which will have to be addressed in future longitudinal studies.
We have previously demonstrated that aCL may participate in platelet activation [6, 11] , and those autoantibodies are commonly found in SLE patients in conjunction with the development of APS. In the current study we made the novel observation that SLE patients with aCL had decreased platelet size, and in vitro, the addition of aCL markedly decreased platelet size. This observation helps to provide mechanistic insight into the decreased platelet size observed in patients with APS, where most patients will have aCL. However, it is important to note that patients without aPL had decreased platelet size. Further, patients with RA and systemic scleroderma, known to have ongoing platelet activation [7, 11, 44] , had a trend towards decreased platelet size. Thus we propose that aCL may participate in regulating platelet size, but several mechanisms likely contribute in this process. Those mechanisms may include, but are not limited to, shear stress and immune complexes, both prevalent in all of the systemic rheumatic disorders and known to participate in the formation of PMPs [45, 46] .
The reason for the uniformly decreased platelet size and its relation to platelet activation in SLE is not completely understood. Upon platelet activation, the platelet undergoes a shape change, with both alpha granules (containing P-selectin) and dense granules (containing serotonin) fusing with the plasma membrane (or open canonical system) and releasing their contents, contributing to a local prothrombotic and inflammatory environment. The platelet shape change and additional granular membranes fused with the plasma membrane are thought to increase, rather than decrease, platelet size. However, exocytosis of serotonin-containing dense granules has been demonstrated upon platelet activation [47] , implying that not all platelet activation will lead to granule plasma membrane fusion and increased platelet size. Further, it has been shown that upon ectosomal release of MPs, the platelet size will decrease, at least initially [47, 48] , consistent with our findings. Therefore, it is possible that aCL may induce a distinct activation pathway [49] , resulting in continuous exocytosis of dense granules and MP generation, contributing to their overall decreased size. However, platelets do not release only PMPs upon activation. Platelet apoptosis leads to prominent release of PMPs concomitant with reduced platelet size [20] . Although SLE patients are known to have increased apoptosis, we are not aware of any study specifically analysing platelet apoptosis in SLE, and no marker of platelet apoptosis was included in the current study. Thus the underlying signalling events, as well as the cause for reduced platelet size, for example, budding of PMPs upon activation or apoptosis, will have to be evaluated in more detail in upcoming studies.
In conclusion, we made the novel observation that SLE patients have a reduced platelet size as compared with healthy individuals, related to ongoing platelet activation and APS, even after adjusting for cardiovascular risk factors. Further studies are warranted to determine the potential predictive value of platelet size for complications in SLE, as well as the causative agent(s) participating in the generation of small platelets in SLE. 
